Sponsor: Otsuka Pharmaceutical Development & Commercialization
Study: 331-201-00079 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole as Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder.
Description: This study is being conducted to determine if Rexulti (brexipiprazole) is effective for patients who suffer from Depression and who have only partly responded to an antidepressant. Participants will have Rexulti added to their current antidepressant. Those who respond successfully to the Rexulti will subsequently be randomized to placebo or a continuation of the Resulti.
Demographics: Males and females with a primary diagnosis of major depression.
Study Coordinator: Christina Ward, Kayelee Auer, Camille Pommerville